Exploratory Study of OPC-12759 Ophthalmic Suspension

NCT01493180 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Keratoconjunctival Epithelial Disorder

Interventions

DRUG: OPC-12759 ophthalmic suspension
DRUG: Sodium hyaluronate ophthalmic solution

Sponsor

Otsuka Pharmaceutical Co., Ltd.